CORE Biomedicine Secures $21 Million in Latest Series A Funding Round

CORE Biomedicine secured $21 million in its latest Series A, adding another data point to the Healthcare & Life Sciences funding market.

CORE Biomedicine Raises $21 million in Funding

CORE Biomedicine Secures $21 Million Series A Venture Financing and Receives AMED Grant Award to Advance Novel Cancer Therapeutics. We look forward to collaborating with CORE Biomedicine to advance its cutting-edge drug pipeline and address unmet medical needs for global patients by delivering better clinical benefits." About CORE Biomedicine Founded by former leaders of H3 Biomedicine, CORE Biomedicine is developing the next generation of precision medicines by going beyond genomics.

Investors Behind the Funding

The round was backed by UTokyo Innovation Platform Co. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

CORE Biomedicine operates in Healthcare & Life Sciences. CORE Biomedicine's financing adds to recent private-market activity.

Strategic Use of Funds

Advance Novel Cancer Therapeutics

Looking Ahead

This venture financing and AMED's support represent a major milestone for CORE Biomedicine and validate our vision for a new generation of oncology medicines,

Source reference: original announcement/article.